Company Description (as filed with the SEC)
We are a specialty biopharmaceutical company focused on commercializing KRYSTEXXA throughout the world. KRYSTEXXA was approved for marketing by the U.S. Food and Drug Administration, or FDA, on September 14, 2010 and became commercially available in the United States by prescription on December 1, 2010, when we commenced sales and shipments to our network of specialty and wholesale distributors. On January 7, 2013, our wholly owned subsidiary, Savient Pharma Ireland Limited was granted a marketing authorization from the European Commission for KRYSTEXXA to be marketed in the European Union, or EU. KRYSTEXXA was approved in the EU for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated. ... More ...